MUSK and myasthenia gravis: Rituximab, a chimeric mouse-human monoclonal antibody targeting the B cell surface antigen CD20, is utilized in refractory AChR-positive and MuSK-positive MG, with strong evidence supporting early intervention in MuSK-MG [64,67].